Skip to main content

Biogen Contract manufacturing revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

Contract manufacturing revenue at Biogen came to $135.9M for the quarter to 30 Sep 2026, down 4.0% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$252.9MSep 2023$105.3MDec 2023$152.2MMar 2024$100.0MJun 2024$221.9MSep 2024$118.0MDec 2024$282.3MMar 2025$225.0MJun 2025$141.5MSep 2025$237.2MMar 2026$232.4MJun 2026$135.9MSep 2026
Biogen Contract manufacturing revenue, every reported period
Period endingContract manufacturing revenueChange on a yearFiled
30 Sep 2026$135.9Mdown 4.0%28 Oct 2026
30 Jun 2026$232.4Mup 3.3%29 Jul 2026
31 Mar 2026$237.2Mdown 16.0%29 Apr 2026
30 Sep 2025$141.5Mdown 36.2%30 Oct 2025
30 Jun 2025$225.0Mup 125.0%31 Jul 2025
31 Mar 2025$282.3Mup 85.5%1 May 2025
31 Dec 2024$118.0Mup 12.1%12 Feb 2025
30 Sep 2024$221.9Mdown 12.3%30 Oct 2024
30 Jun 2024$100.0Mdown 45.4%1 Aug 2024
31 Mar 2024$152.2Mdown 50.4%24 Apr 2024
31 Dec 2023$105.3Mdown 39.8%14 Feb 2024
30 Sep 2023$252.9Mup 121.5%8 Nov 2023
30 Jun 2023$183.1Mup 125.5%25 Jul 2023
31 Mar 2023$306.9Mup 546.1%25 Apr 2023
31 Dec 2022$174.8Mup 53.9%15 Feb 2023
30 Sep 2022$114.2Mdown 20.6%25 Oct 2022
30 Jun 2022$81.2Mdown 6.8%20 Jul 2022
31 Mar 2022$47.5Mdown 42.9%3 May 2022
31 Dec 2021$113.6Mdown 5.0%3 Feb 2022
30 Sep 2021$143.8Mup 30.7%20 Oct 2021
30 Jun 2021$87.1Mdown 78.0%22 Jul 2021
31 Mar 2021$83.2Mdown 11.5%22 Apr 2021
31 Dec 2020$119.6Mdown 2.0%3 Feb 2021
30 Sep 2020$110.0Mup 18.2%21 Oct 2020
30 Jun 2020$395.5Mup 276.0%22 Jul 2020
31 Mar 2020$94.0Mdown 64.4%23 Apr 2020
31 Dec 2019$122.1Mdown 17.4%6 Feb 2020
30 Sep 2019$93.1Mup 1.3%22 Oct 2019
30 Jun 2019$105.2Mup 33.0%24 Jul 2019
31 Mar 2019$264.1Mup 87.8%24 Apr 2019
31 Dec 2018$147.8M—6 Feb 2019
30 Sep 2018$91.9Mup 198.4%23 Oct 2018
30 Jun 2018$79.1Mup 280.3%24 Jul 2018
31 Mar 2018$140.6M—24 Apr 2018
30 Sep 2017$30.8M—24 Oct 2017
30 Jun 2017$20.8M—25 Jul 2017

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.